Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

Journal of Immunology

Volumn 183, Issue 8, 2009, Pages 4921-4930

  Carlsten, Mattias ^a,b   Norell, Håkan ^b,c   Bryceson, Yenan T ^a   Poschke, Isabel ^b   Schedvins, Kjell ^a   Ljunggren, Hans Gustaf ^a   Kiessling, Rolf ^b   Malmberg, Karl Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CYTOCHROME P450 2B4; HLA ANTIGEN CLASS 1; LIGAND; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR DNAX ACCESSORY MOLECULE 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; NATURAL KILLER CELL; OVARY CARCINOMA; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ASCITIC FLUID; CARCINOMA; FEMALE; GPI-LINKED PROTEINS; HUMANS; KILLER CELLS, NATURAL; OVARIAN NEOPLASMS; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS;

EID: 77954107953     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901226     Document Type: Article

References (61)

1. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
2. bright subset. Blood 97: 3146-3151.
3. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640.
4. dim NK cells. Eur. J. Immunol. 31: 3121-3127.
5. Nagler, A., L. L. Lanier, S. Cwirla, and J. H. Phillips. 1989. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 143: 3183-3191. (Pubitemid 20010143)
6. dim NK cells upon activation. J. Immunol. 178: 4947-4955.
7. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
8. Long, E. O. 2008. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 224: 70-84.
9. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214: 73-91.
10. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
11. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. R. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
12. Iguchi-Manaka, A., H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205: 2959-2964.
13. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McClanahan, T. Kitamura, J. Nicholl, G. R. Sutherland, L. L. Lanier, and J. H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573-581.
14. Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carnemolla, C. Cantoni, J. Grassi, S. Marcenaro, N. Reymond, et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198: 557-567.
15. Carlsten, M., N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317-1325.
16. Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64: 9180-9184.
17. El-Sherbiny, Y. M., J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al. 2007. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 67: 8444-8449.
18. Kakehi, S., K. Nakahama, and I. Morita. 2007. Expression and possible role of PVR/CD155/Necl-5 in osteoclastogenesis. Mol. Cell. Biochem. 301: 209-217.
19. Pende, D., R. Castriconi, P. Romagnani, G. M. Spaggiari, S. Marcenaro, A. Dondero, E. Lazzeri, L. Lasagni, S. Martini, P. Rivera, et al. 2006. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107: 2030-2036.
20. Reymond, N., A. M. Imbert, E. Devilard, S. Fabre, C. Chabannon, L. Xerri, C. Farnarier, C. Cantoni, C. Bottino, A. Moretta, et al. 2004. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J. Exp. Med. 199: 1331-1341.
21. Sloan, K. E., J. K. Stewart, A. F. Treloar, R. T. Matthews, and D. G. Jay. 2005. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 65: 10930-10937.
22. Norell, H., M. Carlsten, T. Ohlum, K. J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, and R. Kiessling. 2006. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res. 66: 6387-6394.
23. Vitale, M., G. Pelusi, B. Taroni, G. Gobbi, C. Micheloni, R. Rezzani, F. Donato, X. Wang, and S. Ferrone. 2005. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 11: 67-72. (Pubitemid 40075779)
24. Allavena, P., F. Zanaboni, S. Rossini, A. Merendino, C. Bonazzi, L. Vassena, C. Mangioni, and A. Mantovani. 1986. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. J. Natl. Cancer Inst. 77: 863-868.
25. Lotzova, E., C. A. Savary, and R. B. Herberman. 1987. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Res. 11: 1059-1066.
26. Malmberg, K. J., V. Levitsky, H. Norell, C. T. de Matos, M. Carlsten, K. Schedvins, H. Rabbani, A. Moretta, K. Soderstrom, J. Levitskaya, and R. Kiessling. 2002. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110: 1515-1523.
27. Bryceson, Y. T., M. E. March, D. F. Barber, H. G. Ljunggren, and E. O. Long. 2005. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202: 1001-1012.
28. Belisle, J. A., J. A. Gubbels, C. A. Raphael, M. Migneault, C. Rancourt, J. P. Connor, and M. S. Patankar. 2007. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122: 418-429.
29. Verhoeven, D. H., A. S. de Hooge, E. C. Mooiman, S. J. Santos, M. M. ten Dam, H. Gelderblom, C. J. Melief, P. C. Hogendoorn, R. M. Egeler, M. J. van Tol, et al. 2008. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 45: 3917-3925.
30. Roda-Navarro, P., M. Vales-Gomez, S. E. Chisholm, and H. T. Reyburn. 2006. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc. Natl. Acad. Sci. USA 103: 11258-11263.
31. Coudert, J. D., J. Zimmer, E. Tomasello, M. Cebecauer, M. Colonna, E. Vivier, and W. Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106: 1711-1717.
32. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22. (Pubitemid 39626587)
33. Hellstrom, I., G. Goodman, J. Pullman, Y. Yang, and K. E. Hellstrom. 2001. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 61: 2420-2423.
34. Gilfillan, S., C. J. Chan, M. Cella, N. M. Haynes, A. S. Rapaport, K. S. Boles, D. M. Andrews, M. J. Smyth, and M. Colonna. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205: 2965-2973.
35. Carlsten, M., K. J. Malmberg, and H. G. Ljunggren. 2009. Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int. J. Cancer 124: 757-762.
36. Costello, R. T., S. Sivori, E. Marcenaro, M. Lafage-Pochitaloff, M. J. Mozziconacci, D. Reviron, J. A. Gastaut, D. Pende, D. Olive, and A. Moretta. 2002. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99: 3661-3667.
37. Krockenberger, M., Y. Dombrowski, C. Weidler, M. Ossadnik, A. Honig, S. Hausler, H. Voigt, J. C. Becker, L. Leng, A. Steinle, et al. 2008. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180: 7338-7348.
38. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335-7340.
39. Ogasawara, K., J. A. Hamerman, H. Hsin, S. Chikuma, H. Bour-Jordan, T. Chen, T. Pertel, C. Carnaud, J. A. Bluestone, and L. L. Lanier. 2003. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18: 41-51.
40. Oppenheim, D. E., S. J. Roberts, S. L. Clarke, R. Filler, J. M. Lewis, R. E. Tigelaar, M. Girardi, and A. C. Hayday. 2005. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6: 928-937.
41. Fuchs, A., M. Cella, E. Giurisato, A. S. Shaw, and M. Colonna. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172: 3994-3998. (Pubitemid 38375210)
42. Dunn, C., M. Brunetto, G. Reynolds, T. Christophides, P. T. Kennedy, P. Lampertico, A. Das, A. R. Lopes, P. Borrow, K. Williams, et al. 2007. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204: 667-680.
43. bright and CD56dim natural killer cell subsets. Fertil. Steril. 81(Suppl. 1): 863-868.
44. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052-3057.
45. King, A., P. P. Jokhi, T. D. Burrows, L. Gardner, A. M. Sharkey, and Y. W. Loke. 1996. Functions of human decidual NK cells. Am. J. Reprod. Immunol. 35: 258-260.
46. dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 33: 119-124.
47. bright natural killer cells via the actions of monocyte inflammatory protein 1α. J. Exp. Med. 193: 1199-1212.
48. dim subset. J. Immunol. 179: 4513-4519.
49. Caligiuri, M. A., A. Zmuidzinas, T. J. Manley, H. Levine, K. A. Smith, and J. Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171: 1509-1526.
50. Nishikawa, K., S. Saito, T. Morii, Y. Kato, N. Narita, M. Ichijo, Y. Ohashi, T. Takeshita, and K. Sugamura. 1990. Differential expression of the interleukin 2 receptor β (p75) chain on human peripheral blood natural killer subsets. Int. Immunol. 2: 481-486.
51. Vosshenrich, C. A., M. E. Garcia-Ojeda, S. I. Samson-Villeger, V. Pasqualetto, L. Enault, O. Richard-Le Goff, E. Corcuff, D. Guy-Grand, B. Rocha, A. Cumano, et al. 2006. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 7: 1217-1224.
52. Patankar, M. S., Y. Jing, J. C. Morrison, J. A. Belisle, F. A. Lattanzio, Y. Deng, N. K. Wong, H. R. Morris, A. Dell, and G. F. Clark. 2005. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol. 99: 704-713.
53. Sutherland, C. L., B. Rabinovich, N. J. Chalupny, P. Brawand, R. Miller, and D. Cosman. 2006. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108: 1313-1319.
54. Vitale, M., C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065-2072.
55. Jin, B., J. L. Scott, M. A. Vadas, and G. F. Burns. 1989. TGFβ down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 66: 570-576.
56. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339.
57. Bhat, R., and C. Watzl. 2007. Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies. PLoS ONE 2: e326.
58. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003-5008.
59. Boyiadzis, M., and K. A. Foon. 2008. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther. 8: 1151-1158.
60. Lai, P., H. Rabinowich, P. A. Crowley-Nowick, M. C. Bell, G. Mantovani, and T. L. Whiteside. 1996. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2: 161-173.
61. Gordon, I. O., and R. S. Freedman. 2006. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin. Cancer Res. 12: 1515-1524.